Member Companies
Harlem Biospace is a hub for biotech innovators in NYC and the core of this community are the companies that call Hb home. Through a competitive application cycle every six months, we select some of the region’s most promising early stage ventures to work from Hb.
Our current batch of companies includes:
Developing new drugs for osteoarthritis.
Our drugs may become a first disease-modifying therapy for osteoarthritis. Currently, our lead candidate is being studied in animals, and it has the potential to enter clinical trials in 2021.
Contact: ang.li@avidenceinc.com
BaconBio aims to design and cultivate scalable lab grown meat cell lines for a consumer-focused food product. By taking an R&D focused angle in the burgeoning space, we believe this technology can ultimately scale into other applications including regenerative medicine.
Contact: info@baconbio.com
Bioworkshop is a New York based biotech start-up which is developing microfluidic biochips that model human skeletal tissues and diseases. Our technology will make drug research and development more accurate, quicker and cheaper. Beyond that our platform will eventually facilitate the development of personalised medicines, target other organs and be applied to a range of industries beyond healthcare.
Contact: info@thebioworkshop.com
Genomab Biotech is a biotechnology company located at Harlem Biospace in New York City. Our business primarily focus on developing the next generation of humanized mouse models for use in preclinical studies, translational research, and precision medicine applications. Our NextVivo pharmacology platform can accelerate customers' therapeutic medicine development efforts by providing revolutionary in vivo platforms that closely mirror clinical drug responses.
Contact: info@genomab.com
Haystack Medical is revolutionizing inner ear medicine.
Over 30 million US patients are in need of better options for inner ear maladies. Haystack's technology offers a major breakthrough through its microneedles, providing safe and effective delivery of therapeutics directly into the inner ear. Developed at Columbia University, the technology has been rigorously tested and proven effective in both guinea pig and human cadaveric studies, with 20+ peer-reviewed publications and multiple granted and pending patents.
Contact: aykut@haystackmedical.com
Providing underserved students with hands-on science and engineering educational and mentorship experiences.
Contact: hello@hypothekids.org
Ichor Biologics is a New York City based, pre-clinical biotechnology company that has validated a novel platform for the development of human monoclonal antibodies (Abs) to treat infectious diseases. Ichor aims to utilize this platform to accelerate therapeutic development in the infectious disease space by rapidly producing Ab-based therapeutics that possess high safety and clinical efficacy profiles. The speed and efficacy of the platform will be used to reduce the costs associated with generating intellectual property (IP) through preclinical validation, which will then be leveraged to establish strategic partnerships or licensing agreements thereby accelerating the clinical development of Ichor’s products.
Contact: ralvarez@ichorbiologics.com
MicroRNA for personalized medicine - improved diagnostics & disease management of pulmonary hypertension.
Contact: Gabriele Grunig
Shodex™ manufactures innovative polymer-based HPLC columns including size-exclusion chromatography, HILIC, and sugar analysis columns.
Contact: Ronald Benson
Summit Biomedical Imaging LLC is developing new point-of-care technologies for screening, diagnosis, and margin detection of cancer
Contact: brandc@summitbiomedicalimaging.com
Revolutionary nanomedicine bone targeted drug delivery and controlled release platform technology for the treatment of musculoskeletal conditions.
Contact: wntscientific@yahoo.com
Highlighted Alumni
Developing a novel series of small molecule therapeutics for suppressing tumors.
Grow your own bone.
Developing mitochondrial DNA based biomarkers for cancer and developmental disorders.
Reinventing allergy diagnostics.
Formulating novel antimicrobial polymers.
The future of sweet.
Developing therapeutics to treat diseases caused by imbalances in the gut microbial ecosystem.
Tissue models for rapid testing of the safety and efficacy of drugs with an initial focus on cardiological microtissues.